FDA will review Eisai’s and Biogen’s Alzheimer’s treatment

Andrew Brookes | Image Source | Getty Images

The Food and Drug Administration will make a decision on whether to fully approve Eisai‘s and Biogen‘s Alzheimer’s treatment Leqembi by July 6, the companies announced on Monday.

Leqembi is an antibody treatment that targets brain plaque associated with…

Read Full Article Here CNBC

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.